On August 7, 10x Genomics, Inc. fell 5.26% in after-hours trading, trading at $43.0 per share, with turnover of $4.47 million.

On the news front, the company reported Q2 results showing a per-share loss of $0.14, which beat the analyst consensus estimate of a $0.24 loss. Revenue of $151.0 million also exceeded the $146.8 million estimate. However, revenue declined 12.7% year-over-year from $172.9 million, and the company swung from earnings of $0.28 per share a year earlier to a loss, signaling fundamental deterioration that triggered selling pressure despite the headline beats.

The company raised its full-year revenue guidance to $610 million-$630 million, up from prior guidance of $600 million-$625 million, compared with the analyst consensus of $613.7 million. Nevertheless, the sharp year-over-year revenue contraction and the profit-to-loss reversal weighed on investor sentiment. Earlier in the regular session, the stock had already declined approximately 5% amid broader weakness in the life sciences tools sector.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)